Salomon & Ludwin LLC Sells 21 Shares of Eli Lilly and Company $LLY

Salomon & Ludwin LLC decreased its position in shares of Eli Lilly and Company (NYSE:LLY) by 1.8% during the second quarter, Holdings Channel.com reports. The fund owned 1,119 shares of the company’s stock after selling 21 shares during the quarter. Salomon & Ludwin LLC’s holdings in Eli Lilly and Company were worth $872,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Chicago Partners Investment Group LLC raised its stake in Eli Lilly and Company by 0.5% during the 2nd quarter. Chicago Partners Investment Group LLC now owns 21,322 shares of the company’s stock worth $17,034,000 after acquiring an additional 111 shares during the period. Sigma Investment Counselors Inc. grew its holdings in Eli Lilly and Company by 30.5% during the 2nd quarter. Sigma Investment Counselors Inc. now owns 1,637 shares of the company’s stock valued at $1,276,000 after buying an additional 383 shares in the last quarter. Wingate Wealth Advisors Inc. grew its holdings in Eli Lilly and Company by 79.2% during the 2nd quarter. Wingate Wealth Advisors Inc. now owns 550 shares of the company’s stock valued at $429,000 after buying an additional 243 shares in the last quarter. MB Levis & Associates LLC grew its holdings in Eli Lilly and Company by 17.9% during the 2nd quarter. MB Levis & Associates LLC now owns 191 shares of the company’s stock valued at $149,000 after buying an additional 29 shares in the last quarter. Finally, Joseph P. Lucia & Associates LLC grew its holdings in Eli Lilly and Company by 6.0% during the 2nd quarter. Joseph P. Lucia & Associates LLC now owns 478 shares of the company’s stock valued at $372,000 after buying an additional 27 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, Director Jamere Jackson bought 200 shares of the firm’s stock in a transaction dated Friday, August 8th. The stock was acquired at an average cost of $639.56 per share, for a total transaction of $127,912.00. Following the completion of the transaction, the director owned 9,402 shares in the company, valued at $6,013,143.12. This trade represents a 2.17% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO David A. Ricks bought 1,632 shares of the firm’s stock in a transaction dated Tuesday, August 12th. The shares were acquired at an average price of $644.77 per share, with a total value of $1,052,264.64. Following the completion of the transaction, the chief executive officer owned 546,601 shares of the company’s stock, valued at approximately $352,431,926.77. The trade was a 0.30% increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders purchased 4,514 shares of company stock valued at $2,894,841. 0.13% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. Hsbc Global Res raised shares of Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a report on Wednesday, August 27th. Leerink Partners reissued a “market perform” rating and issued a $715.00 target price on shares of Eli Lilly and Company in a report on Thursday, August 7th. Cantor Fitzgerald set a $925.00 target price on shares of Eli Lilly and Company and gave the company an “overweight” rating in a report on Thursday, October 9th. Weiss Ratings reissued a “hold (c+)” rating on shares of Eli Lilly and Company in a report on Wednesday, October 8th. Finally, Leerink Partnrs lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 7th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average target price of $939.12.

Eli Lilly and Company Stock Down 1.9%

Shares of LLY opened at $803.53 on Friday. The company has a market cap of $760.51 billion, a PE ratio of 52.52, a P/E/G ratio of 1.15 and a beta of 0.47. The business has a fifty day moving average of $753.09 and a 200 day moving average of $765.86. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $935.63. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.59 by $0.72. The company had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.Eli Lilly and Company’s revenue was up 37.6% on a year-over-year basis. During the same period last year, the company earned $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, sell-side analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.